Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $16.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Biomea Fusion in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $29.18.

Biomea Fusion Stock Up 7.9 %

NASDAQ BMEA opened at $2.73 on Wednesday. Biomea Fusion has a twelve month low of $2.35 and a twelve month high of $17.25. The business’s fifty day moving average is $3.52 and its 200 day moving average is $6.24. The company has a market cap of $98.93 million, a price-to-earnings ratio of -0.68 and a beta of -0.26.

Institutional Investors Weigh In On Biomea Fusion

Several institutional investors and hedge funds have recently made changes to their positions in BMEA. Barclays PLC lifted its stake in Biomea Fusion by 156.3% in the third quarter. Barclays PLC now owns 39,620 shares of the company’s stock valued at $401,000 after buying an additional 24,162 shares during the period. Geode Capital Management LLC increased its stake in shares of Biomea Fusion by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 601,479 shares of the company’s stock valued at $6,076,000 after acquiring an additional 4,291 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Biomea Fusion during the 4th quarter valued at $58,000. FMR LLC boosted its stake in Biomea Fusion by 0.7% during the third quarter. FMR LLC now owns 5,431,525 shares of the company’s stock worth $54,858,000 after acquiring an additional 39,959 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Biomea Fusion by 3.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 208,391 shares of the company’s stock worth $2,105,000 after purchasing an additional 7,551 shares during the period. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.